ESSA Pharma agrees to all-cash acquisition by XenoTherapeutics for ~$1.91/sh plus CVRs

ESSA Pharma Inc.

Shareholders receive ~$1.91 per share cash (initial distribution + closing payment) plus CVRs up to $0.06 per share.
Transaction backed by XOMA Royalty; implemented via BCBCA plan of arrangement requiring 66⅔% shareholder and court approval.
Deal expected to close in H2 2025; includes $2.5M termination fee payable by ESSA under certain circumstances.
Board and Transaction Committee unanimously recommend; officers/directors owning ~2.23% of shares support deal.
ESSA plans to wind down operations; transaction provides expedited cash return vs. liquidation.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.